TSHA Latest Press Releases

-- November 5, 2026 --

Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12 Globe Newswire 8:00 AM

-- October 2, 2026 --

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 8:00 AM

-- October 1, 2026 --

Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting Globe Newswire 8:00 AM

-- September 4, 2026 --

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 8:00 AM

-- August 11, 2026 --

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 4:00 PM

-- August 7, 2026 --

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 8:00 AM

-- August 4, 2026 --

Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11 Globe Newswire 4:00 PM

-- August 3, 2026 --

Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome Globe Newswire 8:00 AM

-- June 25, 2026 --

Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting Globe Newswire 4:01 PM

-- June 24, 2026 --

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants Globe Newswire 10:33 PM

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants Globe Newswire 4:01 PM

-- June 22, 2026 --

Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome Globe Newswire 8:00 AM

Market Data Delayed 15 Minutes